In addition to Wegovy, its sister drug Ozempic, indicated for diabetes, and NVO’s oral GLP-1 agonist Rybelsus have also been selected for the negotiation round. Other drugs included in the list ...

Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 per cent in 2024 to 100 billion Danish ...

The company is spending billions to ramp up its Wegovy output as demand soars. "Emissions come with growth," said Katrine DiBona, corporate vice president of global public affairs and ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of ... to Novo Nordisk—said he and other drug makers would appeal to the next administration, saying, "They need ...

Novo Nordisk reported soaring sales for weight loss drug Wegovy (James Manning/PA) Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo ...

The move could mean savings for consumers. Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly with drug manufacturers ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

WASHINGTON — Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers ...

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy ... elect did not respond to a request for comment. The bulk of staff working ...

Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo Nordisk (NVO) predicted growth will slow this year. The Danish pharmaceutical company has ...